Patents
Literature
5 results about "Mucoadhesion" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bioadhesion is the mechanism by which two biological materials are held together by interfacial forces. When relating this mechanism to the pharmaceutical sciences, mucoadhesion describes the attractive forces between a biological material and mucus or mucous membrane. Mucous membranes adhere to epithelial surfaces such as the gastrointestinal tract (GI-tract), the vagina, the lung, the eye, etc. They are generally hydrophilic as they contain many hydrogen macromolecules due to the large amount of water (approximately 95%) within its composition. However, mucin also contains glycoproteins that enable the formation of a gel-like substance. Understanding the hydrophilic bonding and adhesion mechanisms of mucus to biological material is of utmost importance in order to produce the most efficient applications. For example, in drug delivery systems, the mucus layer must be penetrated in order to effectively transport micro- or nanosized drug particles into the body.
Mucoadhesive microgel compositions and methods for using the same
Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions.
Owner:CENT NAT DE LA RECH SCI (C N R S) +1
A mucoadhesive film comprising a pharmaceutically active agent and uses thereof
PendingEP4518855A4Nervous disorderHydroxy compound active ingredientsPolymer sciencePharmacy medicine
A mucoadhesive composition and method for the administration of the pharmaceutically effective agents is provided. Specifically, a mucoadhesive composition, composed of a mucoadhesive polymer and a plurality of active agents having different water solubility embedded therewithin; and use thereof such as for the treatment of a disease is provided.
Owner:SHORT WAVE PHARMA INC
Topical antiviral compositions comprising hyaluronic acid and carrageenan
Disclosed are topical compositions comprising hyaluronic acid or salts thereof and iota-carrageenan, preferably in a mucoadhesive matrix containing ascorbyl palmitate and choline alfoscerate. The compositions according to the invention are useful for topical treatment of Herpesvirus infections.
Owner:RICERFARMA
A recombinant lactococcus microcapsule, its preparation method and application
ActiveCN121287651BHas antioxidant functionAbility to express antioxidant enzymesPeptide/protein ingredientsAntipyreticStaphylococcus lactisBowels diseases
This invention relates to a recombinant *Lactococcus lactis* microcapsule, its preparation method, and its applications, belonging to the field of genetic engineering. To address the technical problems of low safety, high side effects, unstable efficacy, and insufficient targeting in existing methods for treating or alleviating inflammatory bowel disease (IBD), this invention provides a recombinant *Lactococcus lactis* microcapsule. By integrating a fusion gene encoding catalase and superoxide dismutase, a recombinant *Lactococcus lactis* with antioxidant function is constructed. The recombinant *Lactococcus lactis* is then coated with a mucosa-adhesive chitosan and sodium alginate composite nanomaterial to obtain a microcapsule with antioxidant enzyme expression capabilities and a nano-protective coating. The recombinant *Lactococcus lactis* microcapsule provided by this invention can enhance the activity and bioavailability of orally delivered substances under the harsh acidic environment and complex physiological barriers of the gastrointestinal tract, providing a new strategy and experimental evidence for the clinical prevention and treatment of IBD.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY